secwatch.observer — SEC 8-K summary
======================================

Issuer:     IMPACT BIOMEDICAL INC. (IBO)
CIK:        0001834105
Form:       8-K
Filed at:   2024-10-08T23:59:59+00:00
Accession:  0001493152-24-040465
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Impact Biomedical enters three-year CEO employment agreement with Frank Heuszel
-------------------------------------------------------------------------------

- Term from Oct 3, 2024 to Oct 3, 2027; base salary $200K year 1, $250K years 2 and 3.
- Mandatory bonus: $150K year 1, $100K each year 2 and 3; discretionary bonuses eligible.
- Option grant of 300,000 shares at $3.00/share under 2023 Equity Incentive Plan.
- Agreement defines termination for cause and good reason; executive remains CEO, Chairman, President.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1834105/000149315224040465/0001493152-24-040465-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1834105/000149315224040465/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-040465

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer